PLXHealthcare · BiotechnologyThe 1 Wall Street analysts covering Protalix Biotherapeutics, Inc. hold a median 12-month price target of $11 — +358.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 83 of 100 as at 24 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Protalix Biotherapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (100): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Accruals (14): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on PLX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +358.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 19 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 21 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 3 Feb 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 14 Nov 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 31 Oct 2023 | HC Wainwright & Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PLX appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 25 Aug 2026, Protalix Biotherapeutics, Inc. returned +50.0% against +20.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 58% of US stocks
Cheaper than 49% of US stocks
Cheaper than 36% of US stocks
Cheaper than 50% of US stocks
Higher than 77% of US stocks
Higher than 99% of US stocks
Higher than 95% of US stocks
Higher than 82% of US stocks
Higher than 85% of US stocks
Higher than 88% of US stocks
Higher than 97% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Protalix Biotherapeutics, Inc. has a market value of $191.8M and an enterprise value of $160.3M.
Revenue in the twelve months to 31 Mar 2026: $76.4M. The latest quarter grew 27.1% year on year.
Net income over the same four quarters: $15.3M, a 20.1% net margin.
Free cash flow in the twelve months to 31 Mar 2026: $13.0M, after $2.1M of capital spending.
Trailing P/E: 10.3×; forward P/E: 3.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Protalix Biotherapeutics, Inc. employs 226 people — $338K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Protalix Biotherapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Seeking Alpha published a transcript of Protalix BioTherapeutics, Inc.'s Q2 2026 earnings call, covering the company's second-quarter results for that period.
Why it matters — A PLX watcher would care because the earnings call transcript provides direct insights into the company's Q2 2026 financial performance and management commentary.
Protalix BioTherapeutics reported second quarter 2026 financial results, with product sales of Elfabrio driving revenue up to $19.8 million for the quarter and $53.6 million year-to-date, including a previously reported $25.0 million Chiesi milestone payment. The company achieved year-to-date profitability with net income of $22.1 million, reiterated full-year 2026 revenue guidance of $78.0-83.0 million, and noted that its PRX-115 Phase 2 study is advancing as planned with top-line results expected in the second half of 2027.
Why it matters — The results show revenue growth, year-to-date profitability, maintained guidance, and an on-track PRX-115 development program, key indicators for PLX watchers.
Protalix BioTherapeutics announced it will release its second quarter 2026 financial results and provide a business update on August 12, 2026, followed by a conference call and webcast at 8:00 a.m. EDT.
Why it matters — PLX watchers will be interested in the financial results and business update for the quarter ended June 30, 2026, as they provide insight into the company's recent performance and progress.
The 1 Wall Street analysts covering Protalix Biotherapeutics, Inc. have a median 12-month price target of $11, with estimates ranging from $10 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 1 analysts covering Protalix Biotherapeutics, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Protalix Biotherapeutics, Inc. 83 out of 100 across roughly 4,600 US stocks as at 24 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 24 Aug 2026, Protalix Biotherapeutics, Inc. ranks 83 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (100 of 100).
No one can know that. What the data says: the median 12-month target from 1 analysts implies +358.3% from the last close, and Ticker Nerd's factor model ranks Protalix Biotherapeutics, Inc. 83 out of 100 as at 24 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Protalix Biotherapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PLX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $12 over the next 12 months.
Protalix Biotherapeutics, Inc. returned +50.0% over the 12 months to 25 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Protalix BioTherapeutics, Inc. is a biopharmaceutical company focused on developing, producing, and commercializing recombinant therapeutic proteins using its proprietary ProCellEx plant cell-based expression system.
The most recent item we track (Seeking Alpha, 12 Aug 2026): "Protalix BioTherapeutics, Inc. (PLX) Q2 2026 Earnings Call Transcript". Seeking Alpha published a transcript of Protalix BioTherapeutics, Inc.'s Q2 2026 earnings call, covering the company's second-quarter results for that period.
Protalix BioTherapeutics, Inc. is a biopharmaceutical company focused on developing, producing, and commercializing recombinant therapeutic proteins using its proprietary ProCellEx plant cell-based expression system. The company’s current portfolio centers on treatments for rare diseases, including Elelyso for Gaucher disease and Elfabrio for adult patients with Fabry disease. Protalix also advances a pipeline of plant cell-expressed candidates such as PRX-115 for gout and PRX-119 for NETs-related diseases, reflecting its emphasis on enzyme replacement therapies and other biologic approaches for conditions with limited treatment options. Based in Karmiel, Israel, Protalix serves global markets through product commercialization and partnership-based development across its specialty biopharmaceutical programs.
CEO Mr. Dror Bashan · 226 employees · United States · https://www.protalix.com
